Comparative Pharmacology
Head-to-head clinical analysis: DOXY 100 versus MINOCYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 100 versus MINOCYCLINE HYDROCHLORIDE.
DOXY 100 vs MINOCYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
Bacteriostatic antibiotic that reversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
200 mg orally or intravenously once, followed by 100 mg every 12 hours; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Terminal elimination half-life: 11–17 hours (mean ~15 hours in normal renal function); prolonged to 18–30 hours in renal impairment; context: allows twice-daily dosing, but accumulation can occur in hepatic/renal dysfunction.
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Renal (approximately 10% unchanged; higher in impaired renal function), biliary/fecal (major route via feces as unchanged drug and metabolites, up to 70% overall elimination through hepatobiliary system).
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic